Cost-effective use of NSAIDs: Issues pertinent to coxib use in managed care

American Journal of Managed Care

Volumn 8, Issue 17 SUPPL., 2002, Pages

  Fendrick, A Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARTHROTEC; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NABUMETONE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; RISPERIDONE; RIZATRIPTAN; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPEPSIA; ECONOMIC EVALUATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALTH CARE SYSTEM; HUMAN; LOW DRUG DOSE; MANAGED CARE; MEDICAL DECISION MAKING; MIGRAINE; NAUSEA; OSTEOARTHRITIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; STOMACH DISEASE; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; ECONOMICS, PHARMACEUTICAL; HUMANS; MANAGED CARE PROGRAMS; OSTEOARTHRITIS; UNITED STATES;

EID: 0036859892     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Retail and Provider Perspective, National Prescription Audit, 1999-2000. Plymouth, PA: IMS Health; 2000.
2. Infoscan Services, Internal Analgesics Category, Total Food, Drug and Mass Merch, 52 Weeks Ending July 16, 2000. Plymouth, Pa: Information Resources, Inc; 2000.
3. Nonprescription Drugs USA 1999, Internal Analgesics Product Category. Little Falls, NJ: Kline & Company, Inc; 1999.
4. World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee (Technical Report Series 804). Geneva, Switzerland: World Health Organization; 1990.
5. Bloom B.S. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84(suppl 2A):20-24.
6. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43:378-385.
7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
8. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastro-intestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321-2332.
9. Scheiman JM. GI outcomes: Evidence for risk reduction in patients using coxibs. Am J Manag Care. 2002;8(suppl):S554-S564.
10. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(suppl 56):18-24.
11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
12. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5:137-142.
13. Mullins CD, Morris LS, Perfetto EM, Ogilvie SD. Pharmacoeconomics of NSAIDs: Beyond bleeds. J Manag Care Pharm. 1997;3:425-430.
14. Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ. 1999;2:45-55.
15. Lapane KL, Spooner JJ, Pettitt D. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care. 2001;7:402-408.
16. Zhao SZ, Arguelles LM, Dedhiya SD, Morgan DG. Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care. 1999;5:1285-1295.
17. Wolfe F. The importance of gastrointestinal (GI) symptom severity in rheumatoid and osteoarthritis: Symptom rates and risk for GI hospitalization. J Rheumatol. 2000;27:1661-1667.
18. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol. 1992;45:187-195.
19. Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol. 1995;22:708-712.
20. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: The size of the problem. J Clin Gastroenterol. 1989;11: 158-162.
21. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
22. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.
23. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg. 2000;91:1221-1225.
24. Reicin A, Brown J, Jove M, et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop. 2001;30:40-48.
25. Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg. 2002;94:55-59.
26. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther. 2001;23:228-241.
27. Bekker A, Cooper PR, Frempong-Boadu A, Babu R, Errico T, Lebovits A. Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery. Neurosurgery. 2002;50:1053-1057; discussion 1057-1058.
28. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002;23(suppl):S35-S40.
29. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: An open label pilot study. Cephalalgia. 2002;22:309-312.
30. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029-1034.
31. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submission Involving Economic Analyses. Canberra, Australia: Australian Government Publishing Service; 1995.
32. Glennie JL, Torrance GW, Baladi JF, et al. The revised Canadian guidelines for the economic evaluation of pharmaceuticals. PharmacoEconomics. 1999;15:459-468.
33. Lovatt B. The United Kingdom guidelines for the economic evaluation of medicines. Med Care. 1996;34(suppl):DS179-DS181.
34. Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis. 2002;61:370-373.
35. Ko CW, Deyo RA. Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease. J Gen Intern Med. 2000;15:400-410.
36. Kamath CC, Maradit-Kremers H, Vanness DJ, O'Fallon WM, Gabriel S.E. Cost-effectiveness of alternative drug therapies in knee osteoarthritis [abstract]. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, California.
37. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. JAMA. 2002;287:64-71.
38. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol. 2000;27:1020-1027.
39. Van Dieten HE, Korthals-De Bos IB, Van Tulder MW, Lems WF, Dijkmans BA, Boers M. Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2000;59:753-759.
40. Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1994;37:333-341.
41. Drummond M, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford, England: Oxford University Press; 1997.
42. Pettit D, Goldstein JL, McGuire A, et al. Overview of the Arthritis Cost Consequence Evaluation System (ACCES): A pharmacoeconomic model for celecoxib. Rheumatology. 2000;39(suppl 2):33-42.
43. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med. 1991;91:213-222.
44. Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology. 2000;39(suppl 2):43-50.
45. Haglund U, Svarvar P. The Swedish ACCES model: Predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology. 2000;39(supp 2): 51-56.
46. Chancellor JV, Hunsche E, De Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. PharmacoEconomics. 2001;19(suppl 1):59-75.
47. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. PharmacoEconomics. 2001;19(suppl 1):49-58.
48. Pellissier JM, Straus WL, Watson DL, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal antiinflammatory drugs for the treatment of osteoarthritis. Clin Ther. 2001;23:1061-1079.
49. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. PharmacoEconomics. 2001;19:1039-1049.
50. Attard CL. Economic implications of comparing rofecoxib and NSAIDs in rheumatoid arthritis in Ontario, Canada [abstract]. Paper presented at: Annual European Congress of Rheumatology of the European League Against Rheumatism; June 12-15, 2002; Stockholm, Sweden.
51. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis. Arthritis Rheum. 2002;47:36-43.
52. Armstrong CP, Blower AL. Non-steroidal antiinflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527-532.
53. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 1987.82:1153-1158.
54. Bijlsma JW. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: An international multicentre collaborative study. Aliment Pharmacol Ther. 1988;2(suppl 1):85-95.
55. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol. 1996;15:450-456.
56. Maetzel A, Anderson J, Burke TA, Arguelles LM, Pettitt D. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, California.
57. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: Risk reduction by COX-2 therapy. J Rheumatol. 2002;29:467-473.
58. McMahon AD, Evans JM, White G, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol. 1997;50:351-356.
59. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
60. Makuch R, Wentworth C, Burke TA, Zhao S. Switching of prescription antiinflammatory therapy among enrollees in a U.S. managed care organization: A comparison of non-selective NSAIDs, celecoxib, and rofecoxib [abstract]. Paper presented at: Annual European Congress of Rheumatology of the European League Against Rheumatism; June 12-15, 2002; Stockholm, Sweden.
61. Michaud K, Wolfe F, Pettitt D, Burke TA, Zhao S. Patients remain on COX-2 NSAIDs longer than non-specific NSAIDs: A measure of comparative drug effectiveness [abstract]. Paper presented at: Annual European Congress of Rheumatology of the European League Against Rheumatism; June 12-15, 2002; Stockholm, Sweden.
62. Schnitzer TJ, Kong SX, Mavros P. Persistence of use of selective COX-2 inhibitors versus nonselective NSAIDs: Analyses of a large pharmacy database in the United States [abstract]. Paper presented at: Annual European Congress of Rheumatology of the European League Against Rheumatism; June 12-15, 2002; Stockholm, Sweden.
63. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-1933.
64. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003.
65. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
66. Laine L, Bombardier C, Ramey DR, Watson DJ, Pellissier JM, Reicin A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (Vioxx GI Outcomes Research) study [abstract]. Paper presented at: Annual European Congress of Rheumatology of the European League Against Rheumatism; June 13-16, 2001; Prague, Czech Republic.
67. Bombardier C, Laine L, Carides G. Healthcare resource utilization for perforations, ulcers and bleeds in the VIGOR (Vioxx GI Outcomes Research) study [abstract]. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, California.
68. Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. MedGenMed. 2001;3:6.
69. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69(suppl 1):S140-S146.